|
|
|
| Effects of glucocorticoid combined with enoxaparin sodium for treating patients with recurrent early abortion on their blocking antibody, leptin, anti-specific antibody, and adiponectin levels |
| Qingdao Municipal Hospital, Qingdao, Shandong Province, 266000 |
|
|
|
|
Abstract To study the effects of glucocorticoid combined with enoxaparin sodium for treating patients with recurrent early abortion on their blocking antibody (BA), leptin (LP), anti-specific antibody (AIA), and adiponectin (ADPN) levels. Methods: 115 patients with recurrent early abortion were selected and were divided into group A and group B(n=57) by random number table method from March 2018 to March 2020. 57 patients in group B were treated with enoxaparin sodium alone, and 58 patients in group A were treated with glucocorticoid combined with enoxaparin sodium. Clinical efficacy, the levels of serum BA, LP, AIA, ADPN, progesterone (P), estradiol (E2), and chorionic gonadotropin (β-hCG), pregnancy outcomes, and the incidence of adverse reaction of the patients were compared between the two groups. Results: After treatment, the total effective rate (91.4%) of the patients in group A was siginificant higher than that (71.9%) of the patients in group B. The positive conversion rates of BA and AIA of the patients in the two groups had increased siginificantly, and which (87.9% and 79.3%) of the patients in group A were siginificant higher than those (64.9% and 54.4%) of the patients in group B (all P<0.05). The levels of serum LP, ADPN, P, E2, and β-hCG of the patients in the two groups were siginificant higher than those before treatment, and which of the patients in group A were siginificant higher than those of the patients in group B (P<0.05). The rate of successful delivery (87.9%) of the patients in group A was siginificant higher than that (66.7%) of the patients in group B, but the rates of ectopic pregnancy (1.7%) and abortion again (0%) of the patients in group A were siginificant lower than those (15.8% and 8.8%) of the patients in group B (P<0.05). There was no siginificant difference in the total incidence of adverse reactions (3.5% vs. 7.0%) of the patients between the two groups (P>0.05). Conclusion: Glucocorticoid combined with enoxaparin sodium for treating patients with recurrent early abortion can improve the curative effect, which may be related to the effective improvement of BA, LP, AIA, and ADPN levels.
|
|
|
|
|
|
|
|
|
